	US 12,109,243 B2
	Bacterial extracellular vesicles
Brian Goodman, Jamaica Plain, MA (US); Baundauna Bose, Cambridge, MA (US); and Christopher J. H. Davitt, Boston, MA (US)
Filed by Evelo Biosciences, Inc., Cambridge, MA (US)
Filed on Dec. 2, 2022, as Appl. No. 18/074,122.
Application 18/074,122 is a division of application No. 16/645,019, granted, now 11,524,037, previously published as PCT/US2018/050211, filed on Sep. 10, 2018.
Claims priority of provisional application 62/669,151, filed on May 9, 2018.
Claims priority of provisional application 62/556,015, filed on Sep. 8, 2017.
Prior Publication US 2023/0210913 A1, Jul. 6, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/74 (2015.01); A61P 35/00 (2006.01)

CPC A61K 35/74 (2013.01) [A61P 35/00 (2018.01)]

19 Claims

1. A method of treating an immune disorder in a subject comprising administering to the subject a pharmaceutical composition comprising isolated bacterial extracellular vesicles (EVs), wherein at least 90% of the total EV and bacteria particles in the pharmaceutical composition are EVs from Prevotella or Veillonella bacteria.